|
Volumn 7, Issue 9, 2012, Pages 757-759
|
Systems drug discovery: A quantitative, objective approach for safer drug development
|
Author keywords
high content screening; metabolomics; natural compounds; synthetic biology; systems biology; systems drug discovery; transcriptomics
|
Indexed keywords
DIGITALIS;
MORPHINE;
OPIATE;
PENICILLIN G;
PURINE DERIVATIVE;
SALICYLIC ACID;
ANTHELMINTIC ACTIVITY;
ANTIFUNGAL ACTIVITY;
ANTIMICROBIAL ACTIVITY;
BARK;
BIOSYNTHESIS;
CANCER THERAPY;
CELL FUNCTION;
DERIVATIZATION;
DRUG COST;
DRUG DEVELOPMENT;
DRUG INDUSTRY;
DRUG ISOLATION;
DRUG MARKETING;
DRUG QUALITY;
DRUG RESEARCH;
DRUG SYNTHESIS;
DRUG TREATMENT FAILURE;
ENDOCYTOSIS;
FERMENTATION;
GENE ACTIVITY;
GENE PRODUCT;
GENE SEQUENCE;
HIGH THROUGHPUT SCREENING;
IMAGING;
IN VITRO STUDY;
LASER SCANNING CYTOMETRY;
LIPID METABOLISM;
MEDICINAL PLANT;
METABOLOMICS;
MITOCHONDRION;
ORGANIC CHEMISTRY;
PEROXISOME;
PHASE 3 CLINICAL TRIAL (TOPIC);
PHENOTYPE;
POLYMERASE CHAIN REACTION;
PRIORITY JOURNAL;
PURIFICATION;
QUANTITATIVE ANALYSIS;
REVIEW;
WILLOW;
DRUG DISCOVERY;
DRUG EVALUATION;
DRUG INDUSTRY;
HUMANS;
|
EID: 84865468939
PISSN: 17460441
EISSN: 1746045X
Source Type: Journal
DOI: 10.1517/17460441.2012.710197 Document Type: Review |
Times cited : (5)
|
References (10)
|